Figshareopen access

Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-Mutated advanced NSCLC in China

Name: Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI–resistant, EGFR-Mutated advanced NSCLC in China
License: Open Access

Jing He (58446) et al.

Figshare · Datasets · License: Open Access

Open Source ↗

cancer cost medicine

medicine, pharmacology, sociology, cancer, science policy, biological sciences not elsewhere classified, cost-effectiveness, sacituzumab tirumotecan

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 298348
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.